



**International Guideline  
Harmonization Group**  
for Late Effects of Childhood Cancer

# International Guideline Harmonization Group Meeting

27 June 2024  
Lucerne

# Guideline development process

- Step 1** Determine **concordances and discordances** among existing guidelines
- Step 2** Formulate **clinical questions** based on discordant guideline areas
- Step 3** **Identify** available **evidence** for formulated clinical questions
- Step 4** **Summarize evidence** in evidence tables and appraise quality of evidence using GRADE
- Step 5** **Formulate recommendations** according to the evidence, clinical considerations, and patient values

# GRADE levels of evidence

⊕⊕⊕⊕ **HIGH**

Further research is unlikely to change the confidence in the estimate of effect

⊕⊕⊕⊖ **MODERATE**

Further research is likely to have an important impact on the confidence in the estimate of effect and may change the estimate

⊕⊕⊖⊖ **LOW**

Further research is very likely to have an important impact on the confidence in the estimate of effect and is likely to change the estimate

⊕⊖⊖⊖ **VERY LOW**

Any estimate of effect is very uncertain.

# Recommendations

**STRONG recommendation “is recommended”**

**MODERATE recommendation “is reasonable”**

**NOT TO DO recommendation “is not recommended”**

# Published guidelines

- Secondary breast cancer (TLO 2013; JCO 2020)
- Cardiomyopathy (TLO 2015; TLO 2023)
- Premature ovarian insufficiency (JCO 2016)
- Male gonadotoxicity (TLO 2017)
- Secondary thyroid cancer (Cancer Treat Rev 2018)
- Ototoxicity (TLO 2019)
- Cancer-related fatigue (JCS 2020)
- Obstetric care (AJOG 2021)
- Subsequent CNS neoplasms (TLO 2021)
- Fertility preservation (TLO 2021)
- Coronary artery disease (EJC, 2021)
- Bone mineral density (TLDE 2022)
- Hepatic toxicity (Cancer Treat Rev 2022)
- Mental health problems (TLO 2022)
- Education and employment outcomes (Cancer 2022)
- Hypothalamic-pituitary dysfunction (Endocrine Reviews 2022)
- Dexrazoxane cardioprotection (TLO 2023)
- Pulmonary dysfunction (eClinicalMedicine 2024)

# Guidelines in progress

## **Guideline manuscripts (to be) submitted**

- Nephrotoxicity
- Subsequent colorectal cancer
- Metabolic syndrome

## **In progress**

- **Breast cancer after anthracyclines**
- **Anthracycline equivalence dose for cardiotoxicity**
- **Splenic dysfunction**
- **Growth hormone treatment**
- **Neurocognitive problems**
- **Health promotion**
- Premature ovarian insufficiency update



**International Guideline  
Harmonization Group**  
for Late Effects of Childhood Cancer

# International Guideline Harmonization Group Meeting

## Closing remarks

27 June 2024  
Lucerne

# Guidelines in progress

## Discussed today

- Breast cancer after anthracyclines
- Anthracycline equivalence dose for cardiotoxicity
- Splenic dysfunction
- Growth hormone treatment
- Health promotion
- Neurocognitive problems



# Future topics

- **Metabolic syndrome components:**
  - **hypertension**
  - **hyperlipidemia**
  - **obesity**
  - **diabetes**
- Stroke
- Thyroid dysfunction
- Update male gonadotoxicity surveillance
- Update secondary thyroid cancer
- Fertility preservation for survivors
- Risk stratification follow-up care
- Neurovascular problems
- Melanoma and non-melanoma skin cancer
- Other subsequent neoplasms
- Dental abnormalities
- Eye abnormalities
- Arrhythmias, cardiac valvular abnormalities, pericardial disease
- Risk of congenital abnormalities in offspring of male CAYA cancer survivors
- Osteonecrosis

# Implementation IGHG into local or national guidelines

## Example: European wide update system within PanCare Guidelines Group

### Step 1

- Yearly check if new IGHG guidelines are published

### Step 2

- If new IGHG guidelines available a core group updates current PanCare guideline

### Step 3

- After changes local consensus is reached
- Notification of updates

# Resources

## Resources

- [www.ighg.org](http://www.ighg.org)
- Handbook for guideline development
- IGHG publications
- Interested? Email Renée Mulder ([r.l.mulder@prinsesmaximacentrum.nl](mailto:r.l.mulder@prinsesmaximacentrum.nl))

# Thanks to

## **Core group**

Melissa Hudson  
Leontien Kremer  
Renée Mulder  
Rod Skinner  
Saro Armenian  
Smita Bhatia  
Louis Constine  
Lars Hjorth  
Wendy Landier  
Gill Levitt  
Kevin Oeffinger  
Elvira van Dalen  
Hamish Wallace

**>500 guideline panel members**